A new study published early online in CANCERa peer-reviewed journal of the American Cancer Society, shows that women of color and young women may face elevated risks of developing triple-negative breast cancers, which are often aggressive and do not respond to hormone therapy or targeted therapy. Previous U. To conduct a larger study, Lia Scott, PhD, MPH, of the Georgia State University School of Public Health, and her colleagues analyzed all breast cancer cases diagnosed during from the United States Cancer Statistics database, a population-based surveillance system of cancer registries with data representing 99 percent of the U.
A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer. The primary objective of this study is to compare invasive disease-free survival for ribociclib plus endocrine therapy versus endocrine therapy in patients with HR-positive, HER2-negative, early breast cancer. Breast Cancer.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether it is appropriate for treating a specific disease.
An easy-to-use tool specifically for patients with metastatic breast cancer. Get Started. Carefully selected news and features about metastatic breast cancer research.
Cancer has become one of the ten leading causes of death in India. Breast cancer is the most common diagnosed malignancy in India, it ranks second to cervical cancer. An increasing trend in incidence is reported from various registries of national cancer registry project and now India is a country with largest estimated number of breast cancer deaths worldwide.
The Breast Cancer Now Generations Study was set up in to help understand the causes of breast cancer. This is an enormous project following more thanUK women for 40 years. Identifying these factors and how they combine to cause breast cancer will help us to identify women who are at high risk of developing the disease and offer tailored information about their risk.
Women of color and young women may face elevated risks of developing triple-negative breast cancers, a type of cancer that spreads more quickly than most other types and doesn't respond well to hormone or targeted therapies, a study published in CANCERa peer-reviewed journal of the American Cancer Society, shows. Previous U. To conduct a larger study, researchers in the Georgia State University School of Public Health analyzed all breast cancer cases diagnosed during from the United States Cancer Statistics database, a surveillance system of cancer registries with data representing 99 percent of the U.
TAILORx seeks to incorporate a molecular profiling test into clinical decision making for breast cancer patients. The T rial A ssigning I ndividua L ized O ptions for Treatment Rxor TAILORx, is examining whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment. The majority of women with early-stage breast cancer are advised to receive chemotherapy in addition to radiation and hormonal therapy, yet research has not demonstrated that chemotherapy benefits all of them equally. TAILORx seeks to incorporate a molecular profiling test a technique that examines many genes simultaneously into clinical decision making, and thus spare women unnecessary treatment if chemotherapy is not likely to be of substantial benefit.
This section describes the research behind many of the recommendations and standards of practice discussed in other sections. We present the results from individual studies on many topics ranging from risk factors to treatment to social support. View a list of research summary table topics.
This design was chosen to minimise ascertainment bias, facilitate identification of controls that could be matched for all potential confounding factors and ensure accurate contemporaneous data collection. All women diagnosed with invasive breast cancer aged 40 years or younger during the recruitment period in each centre were eligible to participate. In addition women aged who had a known BRCA1 or BRCA2 gene mutation and were diagnosed with invasive breast cancer within the study period, were also eligible.